Renal Insufficiency
Conditions
Keywords
SP2086, Renal Insufficiency, Pharmacokinetic
Brief summary
The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.
Detailed description
This trial adopt in a parallel, open, single dose study design. The subject was divided into one of five groups according to the degree of renal Insufficiency, which including normal, mild, moderate, severe, and end-stage. All subjects were given SP2086 50mg, and collected the blood samples before and after the medicine taken.
Interventions
DRUGSP2086
all subjects were given SP2086 50mg only one time.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
Yes
Inclusion criteria
* with a body mass index(BMI) between 19 and 28 Kg/m2;Weight:≥50Kg(male),≥45kg(female) * The endogenous creatinine clearance of subjects in groups must meet the standards of Ccr in renal function in installment:mild renal insufficiency:60-89 - ml/min;Moderate renal insufficiency: 30 to 59 ml/min;Severe renal insufficiency: 15-29 ml/min;End-stage renal disease: \< 15 ml/min.Normal renal function: 90 ml/min or more. * Had signed the informed consent himself or herself voluntarily.
Exclusion criteria
* Cannot tolerate oral medicine. * Not control or unstable cardiovascular, respiratory, liver, digestive, endocrine, hematopoietic, the mental or nerve system diseases. * Had the digestive surgery that could affect drug absorption. * The clinical significance of arrhythmia. * Acute hepatitis, chronic liver disease; ALT or AST value was 2 times greater than upper normal limit, Total bilirubin value was 1.5 times greater than upper normal limit. * HBV surface antigen, HCV antibody, or HIV antibody was positive. * history of drug allergy or allergic constitution or family history of allergy. * Had Used hormonal contraception within 3 months; * Had Used DPP - IV inhibitor within 2 weeks; * Had Used traditional Chinese medicine (Chinese herbs, Chinese patent medicine) within 2 weeks; * Had Used acid inhibitors within 2 weeks; * Alcohol, tobacco, drug abusers;alcohol abuse is defined as a day for regular alcohol consumption more than the following standards: beer 570 ml, light beer 750 ml, red wine 200 ml, white wine 60 ml, which including about 20g alcohol;Tobacco is defined as five or more per day. * 2 days before the randomization till to the end ,the patients can not ban alcohol, tobacco, or reference food or drink containing caffeine or xanthine , or vigorous exercise, or there are other factors that can affect drug absorption, distribution, metabolism and excretion * The patient had participated three times or more clinical trial in one year, or one time within 3 months. * Pregnancy or lactation women, or a fertility male or female is not willing to contraception during test. * History of blood donation or participate in blood donation, or by blood transfusion in 3 months prior to screening. * Researchers considered that there was any situation that may cause the participants can't finish this study or bring any obvious risk to subjects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The maximum plasma concentration (Cmax) of SP2086 | up to 96 hours | Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086 |
| The maximum plasma concentration (Cmax) of SP2086 acid | up to 96 hours | Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086 |
| The area under the plasma concentration-time curve (AUC) of SP2086 | up to 96 hours | AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086 |
| The area under the plasma concentration-time curve (AUC) of SP2086 acid | up to 96 hours | AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086 |
Secondary
| Measure | Time frame |
|---|---|
| The number of volunteers with adverse events as a measure of safety and tolerability | up to 96 hours |
Outcome results
None listed